← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksPRTCPrice Target
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

PureTech Health plc (PRTC) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026

Current Price
$16.77
Market reference
Price Target
$57.00
+239.9% Upside
Target Range
$44.00 — $70.00
Wide divergence
Analyst Rating
Buy
2 analysts
Forward P/E—
Trailing P/E8.4x
Forward PEG—
Implied Growth-393.4%
Median Target$57.00
Analyst Spread45.6%

Analysts see +239.9% upside to their consensus target of $57.00. The bullish rating consensus aligns with positive price target gap.

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$16.77
Consensus$57.00
High$70.00
Low$44.00
Model$-9.86
Bear Case
$44
+162.4%
Consensus
$57
+239.9%
Bull Case
$70
+317.4%
Valuation Model TargetsConfidence: 32/100
Bear$-25
Base$-10
Bull$-6

Analyst Ratings Distribution

Breakdown of 2 published analyst recommendations for PRTC

2/2 analysts are bullish
+50
BearishBullish
Weighted analyst sentiment score based on 2 ratings
ConsensusBuy
Coverage2 Analysts
Net Score+50
Bull / Bear100% / 0%
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
2100%
Hold
00%
Sell
00%
Strong Sell
00%
Recommendation Mix100% Buy · 0% Hold · 0% Sell
Buy (2)Hold (0)Sell (0)

PRTC Price Target Analysis

Updated March 1, 2026

As of March 1, 2026, PureTech Health plc (PRTC) has a Wall Street consensus price target of $57.00, based on estimates from 2 covering analysts. With the stock currently trading at $16.77, this represents a potential upside of +239.9%. The company has a market capitalization of $405M.

Analyst price targets range from a low of $44.00 to a high of $70.00, representing a 46% spread in expectations. The median target of $57.00 aligns closely with the consensus average.

The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, PRTC trades at a trailing P/E of 8.4x. Analysts expect EPS to grow -393.4% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $-9.86, with bear and bull scenarios of $-24.50 and $-5.76 respectively. Model confidence stands at 32/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+97.6%
Avg Forward P/E17.3x
Peers with Coverage10 / 10
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
REGNRegeneron Pharmaceuticals, Inc.$107.6B$781.67$857.17+9.7%Buy17.3x48
CNTACentessa Pharmaceuticals plc$3.6B$26.86$37.33+39.0%Buy—11
IMNMImmunome, Inc.$2.0B$21.86$35.29+61.4%Buy—9
CLDXCelldex Therapeutics, Inc.$2.0B$30.09$24.00-20.2%Buy—19
RXRXRecursion Pharmaceuticals, Inc.$1.9B$3.67$11.00+199.7%Hold—10
NRIXNurix Therapeutics, Inc.$1.6B$15.97$31.22+95.5%Buy—17
ROIVRoivant Sciences Ltd.$1.1B$28.94$31.25+8.0%Buy—14
ABCLAbCellera Biologics Inc.$1.1B$3.61$20.17+458.7%Buy—11
ARVNArvinas, Inc.$975M$13.27$13.17-0.8%Buy—26
XNCRXencor, Inc.$918M$12.77$28.75+125.1%Buy—27

Upside Potential Comparison

ABCL
+458.7%
RXRX
+199.7%
XNCR
+125.1%
NRIX
+95.5%
IMNM
+61.4%
CNTA
+39.0%
REGN
+9.7%
ROIV
+8.0%

See PRTC's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is PRTC Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare PRTC vs AGIO

See how PRTC stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

What is the PRTC stock price target for 2026?

The consensus Wall Street price target for PRTC is $57, representing 239.9% upside from the current price of $16.77. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is PRTC a buy, sell, or hold?

PRTC has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $57 implies 239.9% upside from current levels.

Is PRTC stock overvalued or undervalued?

PRTC's current price is $16.77 with a consensus target of $57 (239.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.

How high can PRTC stock go?

The most bullish Wall Street analyst has a price target of $70 for PRTC, while the most conservative target is $44. The consensus of $57 represents the median expectation. Our quantitative valuation model projects a bull case target of $-6 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover PRTC stock?

PRTC is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the PRTC stock forecast?

The 12-month PRTC stock forecast based on 2 Wall Street analysts shows a consensus price target of $57, with estimates ranging from $44 (bear case) to $70 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $-10, with bear/bull scenarios of $-25/$-6.

What is PRTC's fair value based on fundamentals?

Our quantitative valuation model calculates PRTC's fair value at $-10 (base case), with a bear case of $-25 and bull case of $-6. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 32/100.

Should I buy PRTC stock?

Wall Street analysts are very optimistic on PRTC, with a "Buy" consensus rating and $57 price target (239.9% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do PRTC price targets vary so much?

PRTC analyst price targets range from $44 to $70, a 46% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $57 consensus represents the middle ground. Our model's $-25-$-6 range provides an independent fundamental perspective.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.